PURPOSE Serum immunoglobulins (Igs) play a critical role in modulating the immune response by neutralizing pathogens, although little is known about the effect of Igs in development of atherosclerotic cardiovascular disease (ASCVD). Elevated serum Immunoglobulin A (IgA) concentrations have been identified in previous studies in populations with obesity and hypertriglyceridemia, whereas variable concentrations of Immunoglobulin M (IgM) have been observed in the setting of dyslipidemia. METHODS In this cross-sectional study, investigators examined the association of serum Ig concentrations with components of metabolic syndrome, including obesity, diabetes, and dyslipidemia. All consecutive adult patients aged 18 years or older discharged from two academic teaching hospitals with serum Immunoglobulin G (IgG) concentration measured during their admission were evaluated, with a total of 1809 individuals included and stratified into two groups: those with and those without dyslipidemia. RESULTS Mean IgG concentration in individuals with and without dyslipidemia was 997 ± 485 mg/dL and 1144 ± 677 mg/dL, respectively (P <  0.0001). After controlling for confounders in the generalized linear model (GLM), the least square mean IgG concentration in individuals with and without dyslipidemia was 1095 and 1239 mg/dL, respectively (P <  0.0001). The mean IgA and IgM concentrations were not significantly different in individuals with and without dyslipidemia both before and after adjusting covariates. After controlling for confounding variables, all three serum Ig concentrations were not significantly different in individuals with and without diabetes. CONCLUSION Dyslipidemia was associated with a lower mean serum IgG concentration. No association with any serum Ig was indentified in individuals with diabetes. Exploration of the association between alterations in serum Igs and metabolic syndrome and the role of alterations of Ig concentrations in disease progression represents an important step in identification of appropriate targeted treatment options for reducing cardiovascular risk.

中文翻译：

---

评估代谢综合征，肥胖症，糖尿病和血脂异常的成分中血清免疫球蛋白浓度的变化。

目的血清免疫球蛋白（Igs）在通过中和病原体来调节免疫应答中起关键作用，尽管对Igs在动脉粥样硬化性心血管疾病（ASCVD）发生中的作用知之甚少。在先前的研究中，肥胖和高甘油三酯血症人群的血清免疫球蛋白A（IgA）浓度升高，而在血脂异常的情况下观察到了不同浓度的免疫球蛋白M（IgM）。方法在这项横断面研究中，研究人员检查了血清Ig浓度与代谢综合征（包括肥胖症，糖尿病和血脂异常）的相关性。评估了从两家学术教学医院出院期间入院期间测量的血清免疫球蛋白G（IgG）浓度的所有连续18岁或18岁以上的成年患者，包括1809例患者，并将其分为两组：有血脂异常和无血脂异常的两组。结果患有和未患有血脂异常的个体的平均IgG浓度分别为997±485 mg / dL和1144±677 mg / dL（P <0.0001）。在广义线性模型（GLM）中控制混杂因素后，有和没有血脂异常的个体的最小二乘法平均IgG浓度分别为1095和1239 mg / dL（P <0.0001）。在调整协变量前后，患有和未患有血脂异常的个体的平均IgA和IgM浓度均无显着差异。在控制了混杂变量之后，患有和不患有糖尿病的个体的所有三种血清Ig浓度均无显着差异。结论血脂异常与平均血清IgG浓度降低有关。在糖尿病患者中未发现与任何血清Ig相关。探索血清Igs改变与代谢综合征之间的关联以及Ig浓度改变在疾病进展中的作用代表了确定适当的靶向治疗方案以降低心血管风险的重要步骤。在糖尿病患者中未发现与任何血清Ig相关。探索血清Igs改变与代谢综合征之间的关联以及Ig浓度改变在疾病进展中的作用代表了确定适当的靶向治疗方案以降低心血管风险的重要步骤。在糖尿病患者中未发现与任何血清Ig相关。探索血清Igs改变与代谢综合征之间的关联以及Ig浓度改变在疾病进展中的作用代表了确定适当的靶向治疗方案以降低心血管风险的重要步骤。